Research
Our Research and Development area has worked for more than 10 years consolidating a pharmaceutical platform that has allowed the generation of a portfolio of patented products that cover different unresolved oral pathologies.
Innovation
Through our innovative pharmaceutical platform, we create unconventional and easy-to-use products aimed to control various oral pathologies, providing relief to patients.
Well-being for Everyone
At Ingalfarma we strive every day to provide relief to our patients, support health professionals, maintain good relationships with our clients and providers, make sure our collaborators have a good quality of life and be a contribution to society.
ABOUT US
Reinstating the value of oral health.
Oral health is strongly related to people’s general health. We offer solutions beyond oral hygiene.
Ingalfarma is a specialty pharmaceutical company, focused on oral pathologies. Our Research and Development area has worked for more than 10 years consolidating a pharmaceutical platform that has allowed the generation of a portfolio of patented products.
Our product portfolio covers various oral pathologies such as oral mucositis, aphthous stomatitis and other oral injuries due to autoimmune diseases or mechanical damage, cold sores, periodontitis, among others.
Ingalfarma is a specialty pharmaceutical company, focused on oral pathologies. Our Research and Development area has worked for more than 10 years consolidating a pharmaceutical platform that has allowed the generation of a portfolio of patented products.
Our product portfolio covers various oral pathologies such as oral mucositis, aphthous stomatitis and other oral injuries due to autoimmune diseases or mechanical damage, cold sores, periodontitis, among others.
Our Team
Founders
Felipe Galván
Co-Founder and Chief Executive Officer
Felipe has an undergraduate degree in Chemical Engineering a postgraduate degree in Business Administration and studies in Biochemistry at the Universidad de Chile. He also studied at the University of Karlsruhe-TH in Germany, developing research for international companies such as P&G. In his 15 years career, he has managed to stand out, leading multidisciplinary teams in various fields of research, health and industry. Thanks to its experience in science and business, Ingalfarma continues to position itself in the field of bio-business and has obtained important international recognitions.
Dr. Tomás Galván, DDS
Co-Founder and Chief Medical Officer
Tomas is Dental Surgeon from the Universidad de Chile and former professor of Chemistry at the Faculty of Dentistry at the University of Chile. He has presented his line of investigation and discoveries in a large number scientific and clinical meetings as well as in symposiums at the International Association for Dental Research, IADR.
With over 40 years of experience, Dr. Galván has developed many initiatives in the public and private sectors. Scientist and serial entrepreneur, he is responsible for the development pipeline, inventor and author of a large number of international patents.
With over 40 years of experience, Dr. Galván has developed many initiatives in the public and private sectors. Scientist and serial entrepreneur, he is responsible for the development pipeline, inventor and author of a large number of international patents.
Dr. David Rosenberg, DDS, MSc, PhD
Co-Founder and Chief Scientific Officer
David is Dental Surgeon from the Universidad de Chile, he pursued a MSc in Periodontology and Osseointegration at the Catholic University of Leuven (KUL Leuven, Belgium) and PhD at the International University of Catalunya, researching topics in the areas of Periodontology and Oral Medicine.
Since 2009, David serves as the Director of Graduate Studies of the Faculty of Dentistry and part of the academic staff of Department of Oral and Maxillofacial Surgery at the Los Andes University, Chile. Dr. Rosenberg is an established lecturer and well-published researcher in International journals. He is an active member of the European Association of Osseointegration and the Academy of Osseointegration. Today, he is leading the clinical development area and posseses international patents.
Since 2009, David serves as the Director of Graduate Studies of the Faculty of Dentistry and part of the academic staff of Department of Oral and Maxillofacial Surgery at the Los Andes University, Chile. Dr. Rosenberg is an established lecturer and well-published researcher in International journals. He is an active member of the European Association of Osseointegration and the Academy of Osseointegration. Today, he is leading the clinical development area and posseses international patents.
Executive Team
Rafael Carvacho , MBA
General Manager
Rafael is an MBA Executive with over 25 years of experience in pharma Industry, managing high performance teams in commercialization of pharmaceutical in the areas of general medicine, fertility, endocrinology, cardiology and neurology.
He was responsible for P&L and costs allocation, advocacy programs as well as market access strategy for business specialties. Commercial Director & Legal Responsible for Merck KGaA in Peru from 2016 to 2018, today he leads the commercialization of Ingalfarma’s products along countries in Latin America.
He was responsible for P&L and costs allocation, advocacy programs as well as market access strategy for business specialties. Commercial Director & Legal Responsible for Merck KGaA in Peru from 2016 to 2018, today he leads the commercialization of Ingalfarma’s products along countries in Latin America.
Luz María Valenzuela
Commercial Manager
Luz María is a Business Administrator from the Pontificia Universidad Católica de Chile and has a diploma in Design Thinking and Brand Innovation from the Universidad Adolfo Ibáñez. She has experience in marketing areas of large international laboratories, successfully leading marketing strategies aimed at both the end consumer and health professionals.
Today she is in charge of positioning Ingalfarma as an expert company in oral health within the target groups and complying with a demanding commercial plan in the local market.
Today she is in charge of positioning Ingalfarma as an expert company in oral health within the target groups and complying with a demanding commercial plan in the local market.
Gonzalo Leiva
Head of Operations and Logistic
Gonzalo is a professional in the engineering area. First, he got his chemical engineer academic degree in Universidad de Santiago and then the Industrial Civil Engineer academic degree in Universidad de Antofagasta. Gonzalo has 13 year of experience in operations and product manufacturing (chemical products, detergents, disinfectant, among others). To complement this Gonzalo has experience in Quality Management Systems and currently leads the certification of ISO9001:2015 and ISO 13485:2016 standards in Ingalfarma.
Advisors and Directors
Rajesh Lalla, DDS, PhD
International Clinical Advisor
Dr. Lalla is a board-certified clinician and scholar who conducts clinical research on a variety of oral mucosal disorders, including mucositis secondary to cancer treatment, recurrent aphthous stomatitis (canker sores) and oral candidiasis. In addition, Dr. Lalla is also involved in clinical and classroom teaching of Oral Medicine and directs a course on Evidence-based Decision Making. Dr. Lalla serves as Associate Dean for Research in the School of Dental Medicine at University of Connecticut. He also serves on several institutional committees and is a past Chair of the Institutional Review Board, which oversees the conduct of clinical research. Dr. Lalla holds several leadership positions at the international level. He is a past Chair of the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer and the International Society for Oral Oncology (MASCC/ISOO), a member of the MASCC Board of Directors, and President-elect of MASCC. Dr. Lalla has written more than 75 peer-reviewed scientific articles or book chapters, many of them dealing with oral complications in cancer patients.
Pablo Valenzuela, PhD
Director –Scientific Advisor
Dr. Valenzuela earned his Ph.D. degree (1970) in Chemistry at Northwestern University, did a postdoctoral training at University of California San Francisco and held a position as Professor in the Biochemistry Department of that institution.
In 1981, together with W. Rutter and E. Penhoet, founded Chiron Corporation, which a decade later was the second-largest biotechnology company in the world. As Vice President of R&D, Valenzuela was responsible for the development of biotech products with a market value of nearly 8 billion dollars and inventor in more than 50 patents in Chile and abroad. Dr. Valenzuela founded GrupoBios S.A., the first biotech company in Chile and in 1997 he cofounded Fundación Ciencia & Vida.
He is professor of Universidad Católica and Universidad Andrés Bello and is a member of the Chilean Academy of Sciences. In 2002, he was given the Chilean National Award for Applied Sciences. Recently he received the Life Time Achievement Award from the BayBio Association of California.
In 1981, together with W. Rutter and E. Penhoet, founded Chiron Corporation, which a decade later was the second-largest biotechnology company in the world. As Vice President of R&D, Valenzuela was responsible for the development of biotech products with a market value of nearly 8 billion dollars and inventor in more than 50 patents in Chile and abroad. Dr. Valenzuela founded GrupoBios S.A., the first biotech company in Chile and in 1997 he cofounded Fundación Ciencia & Vida.
He is professor of Universidad Católica and Universidad Andrés Bello and is a member of the Chilean Academy of Sciences. In 2002, he was given the Chilean National Award for Applied Sciences. Recently he received the Life Time Achievement Award from the BayBio Association of California.
Cristián Hernández
Director – Business Advisor
Mr Hernández is an experienced business and science executive known for his scientific-entrepreneurship work in Latin America. He previously served as Business Development Manager at Danio Labs Ltd. in Cambridge, England, where he tripled Danio’s European customer portfolio, and managed the company’s merger with Vastox to form Summit PLC.
As a seasoned executive, Mr. Hernández has invested in and mentored numerous Chilean, US and British biotechnology companies. He also lectures on Science and Business at the Biotechnology Ph.D Program of the Universidad Nacional Andrés Bello. He holds a Masters in BioScience Enterprise from the University of Cambridge, England, and an undergraduate degree in Molecular Biotechnology Engineering from the Universidad de Chile.
As a seasoned executive, Mr. Hernández has invested in and mentored numerous Chilean, US and British biotechnology companies. He also lectures on Science and Business at the Biotechnology Ph.D Program of the Universidad Nacional Andrés Bello. He holds a Masters in BioScience Enterprise from the University of Cambridge, England, and an undergraduate degree in Molecular Biotechnology Engineering from the Universidad de Chile.
We care about our environment
Clean Energy:
We feel a strong commitment to the environment. Our products are manufactured in facilities with photovoltaic panels powered by solar energy. Our packaging is recyclable.
Innovation
Quality, collaboration and scientific accuracy for better Innovation:
For the development of its products, Ingalfarma has established through time, alliances at the highest level in Chile and the United States. In the case of the development of our medical devices, we have ISO 9001 and ISO 13485 quality certifications, for Design and Development and Manufacturing Management of medical devices. For the development of medicines, we have established agreements with prestigious national institutions such as Ciencia y Vida Foundation, Universities and Research Centers. Additionally, Ingalfarma works with major consulting companies and clinical research organizations in the United States.
Production facilities
Production with high pharmaceutical standards:
Through our alliance with Knop Laboratories, we have a highly efficient and safe pharmaceutical plant, which has the latest technology and a qualified human team. This allows us to develop and produce our products with the highest pharmaceutical standard, with capacity available for large volumes in liquid and semi-solid production lines.
The pharmaceutical plant has state-of-the-art technology, mainly of German and Italian origin, in addition to rigorous quality controls and permanent preventive maintenance plans, allowing high standards of operation and productivity.
The pharmaceutical plant has state-of-the-art technology, mainly of German and Italian origin, in addition to rigorous quality controls and permanent preventive maintenance plans, allowing high standards of operation and productivity.
contact
If you would like to contact us, please write to us at:
contacto@ingalfarma.com or call us on +56 2 2902 3022
News
DENTOXOL® ENTERS GES PROGRAMME
Ingalfarma announces that its product Dentoxol® has been incorporated into the GES programme of one of the most important health insurance companies in the country,
PUBLICATION OF ESDOM STUDY
Ingalfarma announces the recent publication of its Multicenter, Phase 2, Clinical Trial, for the Evaluation of the Efficacy and Safety of Dentoxol® in the prevention
DIARIO FINANCIERO HIGHLIGHTS THE USE OF DENTOXOL® IN POST-VENTILATED PATIENTS
Ingalfarma performs product tests on COVID-19 patients connected to mechanical ventilators, to treat oral lesions caused by connection to respirators, helping to lessen these adverse